Quantcast

Latest Windhover Information Inc. Stories

2010-10-25 07:30:00

LILLE, France and CAMBRIDGE, Mass., Oct. 25 /PRNewswire/ -- GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced that it has been selected by Windhover as one of the "Top Biopharma Projects To Watch" in 2011 in the cardiovascular/metabolic category. This announcement is part of the conference event...

2010-08-31 06:30:00

EVANSTON, Ill., Aug. 31 /PRNewswire/ -- Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch." They were chosen by a committee that included Windhover Information, the publishers of IN...

2009-11-16 07:00:00

SEATTLE, Nov. 16 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (the "Company") today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partnering. The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior...

2008-11-03 09:00:40

HAYWARD, Calif., Nov. 3 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that two of its programs (MBX-2982 and MBX-8025) have been recognized in Windhover's "Top 10 most interesting projects available for partnering" in their respective categories. MBX-2982, a potential first-in-class treatment for type 2 diabetes, was recognized in the metabolic category and...

2008-10-28 09:00:40

BRISBANE, Calif., Oct. 28, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, today announced that its lead drug candidate, BSI-201, which is in Phase 2 clinical trials for multiple cancer indications, has been selected as one of the Top 10 Most Interesting Oncology Projects Available for Partnering. An independent committee assembled by Windhover Information made the selection. Windhover is a leading...

2008-10-28 09:00:39

Cortria Corporation, a clinical-stage pharmaceutical company focused on developing safe and well-tolerated medicines to fight cardiovascular disease, today announced that TRIA-662 has been selected as one of the Top 10 most promising cardiovascular projects in development. TRIA-662 is currently in Phase 2 clinical development for the treatment of dyslipidemia, an atherogenic disorder characterized by abnormal lipid levels in the bloodstream. "We are excited that Windhover has selected...

2008-10-21 09:00:54

SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that its lead product candidate, picoplatin, has been selected by an independent committee assembled by Windhover Information Inc. as one of the Top 10 most promising oncology projects in development that is available for partnering. "We are pleased that the selection committee has recognized picoplatin as one of the most promising...

2008-09-05 09:00:37

HUNTSVILLE, Ala., Sept. 5 /PRNewswire/ -- Expression Genetics, Inc. (EGEN) announced today that the company's novel TheraPlas(R) cancer drug has been selected as one of the Top 10 most promising oncology products in development available for strategic partnering. The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device...

2008-09-04 03:00:25

WALTHAM, Mass., Sept. 4, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), (XSSE:OXGN) today announced that ZYBRESTAT(tm) (fosbretabulin), the company's lead therapeutic product candidate, has been selected by Windhover Information and an independent expert advisory group, Campbell Alliance, as one of the top 10 most interesting oncology projects available for partnering. ZYBRESTAT is among the first therapeutic products in a novel class of small-molecule drug candidates called vascular...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related